Contact us

Welcome to
Shield Therapeutics

Find out about us

Our People

Driven by and committed to our goals

Our Investors

Delivering more value to our shareholders

Careers

Offering opportunity, ambition and development

Specialty pharmaceutical company

Providing solutions to unmet medical needs.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.

Find out more

Our Products

A treatment for iron deficiency anaemia

Our lead product, Feraccru®, is a novel oral treatment for iron deficiency anaemia (IDA) which, following receipt of marketing authorisation in early 2016, is now commercially available for use initially in patients with inflammatory bowel disease
associated IDA.

Find out more

PM Society Awards Gold winner for Events & Exhibitions

Awarded Company of the Year at the 2016 Bionow Awards

19 Sep 2018

Shield Therapeutics and Norgine B.V. (Norgine) enter into…

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia…

19 Sep 2018

Interim Report for the Six Months Ended 30…

Shield Therapeutics plc, today announces its unaudited interim results for the six months ended 30 June 2018. For further details…

13 Sep 2018

Shield reports completion of recruitment to AEGIS Head…

Shield Therapeutics plc, today announces completion of recruitment of the AEGIS–H2H Phase 3b study of oral Feraccru compared to Intravenous…
View more news articles